Visual Outcome at 4 Years Following Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab (Every 4 Months for 2 Years) for Uveal Melanoma
Open Access
- 1 February 2020
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 138 (2) , 136-146
Abstract
Visual outcome following plaque radiotherapy of choroidal melanoma depends on several factors, including patient age, general health, visual acuity, tumor location/size, subretinal fluid, radioactive isotope, and ultimately radiation retinopathy and papillopathy.1 In a consecutive case study1 of 1106 patients with uveal melanoma of random size treated with plaque radiotherapy (in the prebevacizumab era), ultimate visual acuity was poor at 20/200 or worse in 34% at 5 years and 68% at 10 years. Results of the Collaborative Ocular Melanoma Study2 for medium-size uveal melanoma in 623 patients at 3 years revealed reduction in visual acuity, from visual acuity greater than 20/200 to visual acuity of 20/200 or less in 43% and loss of at least 6 lines of vision in 49%. These poor visual results extend even to the smallest tumors (≤ 3-mm thickness) in 1780 cases that demonstrated Kaplan-Meier 10-year estimates of poor visual acuity (≤20/200) at 54%, despite low risk for metastasis at 9%.3Keywords
This publication has 12 references indexed in Scilit:
- Intravitreal Bevacizumab at 4-Month Intervals for Prevention of Macular Edema after Plaque Radiotherapy of Uveal MelanomaOphthalmology, 2014
- American Joint Committee on Cancer Classification of Posterior Uveal Melanoma (Tumor Size Category) Predicts Prognosis in 7731 PatientsOphthalmology, 2013
- Classification and treatment of radiation maculopathyCurrent Opinion in Ophthalmology, 2010
- Guidelines for Patient Radiation Dose ManagementJournal of Vascular and Interventional Radiology, 2009
- EARLY MACULAR MORPHOLOGICAL CHANGES FOLLOWING PLAQUE RADIOTHERAPY FOR UVEAL MELANOMARetina, 2008
- American College of Radiology White Paper on Radiation Dose in MedicineJournal of the American College of Radiology, 2007
- Vascular Endothelial Growth Factor A in Eyes With Uveal MelanomaArchives of Ophthalmology (1950), 2006
- Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma I. visual acuity after 3 years COMS report no. 16Ophthalmology, 2001
- Plaque Radiotherapy for Uveal MelanomaLong-term Visual Outcome in 1106 Consecutive PatientsArchives of Ophthalmology (1950), 2000
- Radiation Optic NeuropathyOphthalmology, 1982